The role of Gr-MDSC appears interesting as a potential biomarker in NSCLC patients receiving immune-checkpoint inhibitors. Further analyses are needed to confirmed and study in deep the role of these particular cells and their role in cancer response and progression during ICI therapy....
摘要: 【研究背景】肿瘤诱导产生的具有负向调控机体免疫反应的抑制性细胞与肿瘤的发生发展密切相关.越来越多的证据表明一群具有Gr-1和CD11b标志的髓系来源抑制性细胞(myeloid-derived suppressor cells,MDSC)在荷瘤小鼠的脾脏,骨髓,淋巴结,肿瘤原发会议名称: 《第六届全国免疫学学术大会论文集》 会议时间: 2008年 ...
越来越多 的证据表明一 群具有Gr~1 和C I〕 l l b标 志 的髓 系来 源抑 制性 细胞( 卿 e l o id 一 e i rv eds 叩 p r e s s o re e ll s,M DSC )在荷瘤小鼠的脾 脏、骨髓、淋巴结、肿瘤 原发部 位和浸润组 织中 大量 聚积,与肿 瘤进展 关系十分 密切,有关 MD S C与 肿...
担任法定代表人1 担任股东0 担任高管0 所有任职企业1 作为最终受益人1 所属集团0 历史信息 曾担任法定代表人 曾担任股东 曾担任高管 所有曾任职企业 曾为最终受益人0 历史控股企业0 投资信息 控股企业0 间接持股企业0 爱企查图谱 任职全景图 股权穿透图 商业关系图 风险关注 司法案件0 失信被执行人0 限制...
Granulocytic myeloid-derived suppressor cells (GR-MDSC) accumulate in human breastmilkThe present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.NATASCHA KOESTLINCHRISTIAN GILLE...
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation. J Transl Med 2015;13:1-.Pico de Coan~a Y, Wolodarski M, Gentilcore G, Yoshimoto Y, Poschke I, Hansson J, Masucci G V, Kiessling R. Ipilimumab treatment decreases circulating Tregs and Gr...
CD4+CD25+ Tregs (2.5x105) were co-cultured either with CD11b+Gr-1+ MDSCs or with CD11b+ cells at a ratio of 1:1 in the absence or presence of IL-6 (40ng/ml) for 48 hours. IL-10 knockdown (KD) CD11b+Gr-1+ MDSCs were generated by IL-10 siRNA (10nM) transfection for 6 ...
Flow cytometry analysis of circulating Gr-MDSCs and Mo-MDSCs cells in PB from HD and CML patients at diagnosis (D) and during IM therapy.Cesarina, GiallongoNunziatina, ParrinelloDaniele, TibulloPiera, La CavaAlessandra, RomanoAnnalisa, Chi...
Gr-1 Ab increased the percentages and numbers of CD4+ and CD8+ T cells, and decreased the percentages and numbers of MDSCs and G-MDSCs two weeks after BMT.Ming, Shi
Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapyLung cancerImmunotherapyNivolumabMDSCPDL1Acknowledgements section was missingdoi:10.1007/s12094-019-02198-5A. Passaro